{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:21:33Z","timestamp":1781889693968,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies have shown that the cytochrome P450 (<jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>) 3A phenotype marker 4\u03b2\u2010hydroxycholesterol\/cholesterol (4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content> levels than healthy controls. However, 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C ratio in underweight patients has yet to be reported. The aim of this study was to examine potential differences in <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A activity between underweight patients with anorexia nervosa and normal\u2010weight volunteers by measuring plasma 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C ratio. Furthermore, we wished to describe any association between body mass index (<jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>) and 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C ratio in underweight patients. A total of 20 underweight patients and 16 normal\u2010weight volunteers were included in the study, all females. Underweight patients had a median 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C ratio (molar ratio\u00a0\u00d7\u00a010<jats:sup>\u22125<\/jats:sup>) of 2.52 (range, 0.90\u201311.3) compared to 1.29 (0.56\u20132.09) in normal\u2010weight subjects (Mann\u2010Whitney <jats:italic>P\u00a0<\/jats:italic>=\u00a00.0005). 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C ratio was negatively correlated with <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content> in underweight patients (<jats:italic>r\u00a0<\/jats:italic>=\u00a0\u22120.56, <jats:italic>P\u00a0<\/jats:italic>=\u00a00.011), and in the whole study population (<jats:italic>r\u00a0<\/jats:italic>=\u00a0\u22120.67, <jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.0001). This suggests that the negative correlation between 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C and <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>, which has previously been reported between 4\u03b2<jats:styled-content style=\"fixed-case\">OHC<\/jats:styled-content>\/C and body weight in healthy volunteers, extends to underweight patients. The findings indicate that <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A activity increases with decreasing <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>, resulting in higher <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A activity in underweight patients compared to normal\u2010weight subjects. The potential clinical relevance of this needs to be studied further by comparing pharmacokinetics of drugs subjected to <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A\u2010mediated metabolism in underweight vs. normal\u2010weight individuals.<\/jats:p>","DOI":"10.1002\/prp2.430","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T05:46:56Z","timestamp":1536731216000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Elevated 4\u03b2\u2010hydroxycholesterol\/cholesterol ratio in anorexia nervosa patients"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7300-5329","authenticated-orcid":false,"given":"Kristine","family":"Hole","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra L.","family":"Heiberg","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gjestad","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise L.","family":"Mehus","sequence":"additional","affiliation":[{"name":"Department of Medicinal Biochemistry Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"R\u00f8","sequence":"additional","affiliation":[{"name":"Regional Department for Eating Disorders Division of Mental Health and Addiction Oslo University Hospital Oslo Norway"},{"name":"Division of Mental Health and Addiction Institute of Clinical Medicine University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"},{"name":"Department of Pharmaceutical Biosciences School of Pharmacy University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2178-y"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201712200"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0186-9"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f50ee9"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12537"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12492"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2015.03.019"},{"key":"e_1_2_8_10_1","first-page":"8","article-title":"Effects of obesity on the cytochrome P450 enzyme system","volume":"37","author":"Kotlyar M","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.261"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12833"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13248"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9949-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03773.x"},{"key":"e_1_2_8_16_1","unstructured":"FlockhartD.Drug Interactions: Cytochrome P450 Drug Interaction Table. [Indiana University School of Medicine Web site]. 2016.www.medicine.iupui.edu\/CLINPHARM\/ddis\/main-table. Accessed May 28 2018."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197701272960403"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0948-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1266-x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1996.tb00007.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2011.011185"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01702.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2014.10.003"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.72"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep19694"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054171"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.051136"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03309.x"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fprp2.430","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T06:34:18Z","timestamp":1694846058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/prp2.430"],"URL":"https:\/\/doi.org\/10.1002\/prp2.430","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"2018-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00430"}}